What you eat matters
Time of Update: 2022-09-08
The AREDS study, originally initiated in 1996, showed that dietary supplements (500㎎ vitamin C, 400 IU vitamin E, 2㎎ copper, 80㎎ zinc, and 15㎎ beta-carotene) significantly slowed the progression of AMD from intermediate to advanced stages.
Supplementation with fish oil and vitamin D during pregnancy may reduce the risk of croup in infants and young children
Time of Update: 2022-09-07
” Image: Portrait of researcher Dr Nicholas Blostad Source: Dr Nicklas Brustad/European Respiratory SocietyBabies and children under three are less likely to develop croup if mothers take fish oil and vitamin D supplements during pregnancy, according to new results from a clinical trial .
Children's inflammatory myopathy is frequently misdiagnosed, 3 diagnosis and treatment experiences save little lives
Time of Update: 2022-01-27
JDM is a chronic inflammatory myopathy that affects the skin, striated muscle, and other tissues and organs (including the digestive tract, heart, and lungs) in patients aged 0-15 years .
Lung Cancer: The efficacy of brigatinib in the treatment of previously treated ALK+ metastatic non-small cell lung cancer patients: a real-world study
Time of Update: 2021-07-31
g. , in a phase III trial, receiving chemotherapy ALK + NSCLC patients% objective response rate was 45 (95% CI: 37 [ - 53 is), the median progression-free survival ( PFS) was 7.
Arikayce, the first non-tuberculosis branching lung medicine caused by mycobacterium bird, will be approved in the European Union
Time of Update: 2020-08-08
Original source: Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser DeETfor dydd of NTM Lung Infections Caused mac in Non-CF Patients With Treatment.
Arikayce EU is about to be approved: the first drug to treat non-TUBERit mycobacteria (NTM) lung disease caused by bacillus bird type (MAC) !
AstraZeneca Calquence for new crown-first trial to launch large-scale clinical trial
Time of Update: 2020-05-30
On April 14th AstraZeneca announced that it would launch a randomized, global clinical trial to assess the potential of Calquence in treating patients with severe hyperimmune response (cytokine storm)
Afatinib is qualified for priority review in the treatment of non-small cell lung cancer
Time of Update: 2017-10-11
Source: Boehringer Ingelheim, 2017-10-11, announced today that the FDA of the United States has accepted its SNDA application for additional new drugs submitted to gilotinib, which is used for first-l
The domestic market of anti lung cancer drugs has become a blue ocean with various enterprises
Time of Update: 2017-08-31
China's incidence rate of lung cancer is increasing Lung cancer has become the leading cancer incidence rate in China, ranking 2017-08-31 and August 31st At present, the domestic anti lung cancer drug